Research Article
Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia
Table 4
Analysis of infection after CAR-T treatment.
| | Groups | No infection occurs () | Infection occurs () | / | |
| | Age (year) | | | 0.821 | 0.418 | | Gender | | | | | | Male | 8 (40.00) | 10 (66.67) | 2.440 | 0.118 | | Female | 12 (60.00) | 5 (33.33) | | | | CRS grade | | | | | | Grade 1 | 7 (35.00) | 3 (20.00) | 2.426 | 0.489 | | Grade 2 | 6 (30.00) | 5 (33.33) | | | | Grade 3 | 6 (30.00) | 4 (26.67) | | | | Grade 4 | 1 (5.00) | 3 (20.00) | | | | Usage of glucocorticoids | | | | | | Yes | 11 (55.00) | 9 (60.00) | 0.088 | 0.767 | | No | 9 (45.00) | 6 (40.00) | | | | Usage of tocilizumab | | | | | | Yes | 15 (75.00) | 11 (73.33) | 0.013 | 0.911 | | No | 5 (25.00) | 4 (26.67) | | | | Initial WBC (×109/L) | | | 0.139 | 0.891 | | Initial ANC (×109/L) | | | 1.796 | 0.082 | | Initial PLT (×109/L) | | | 0.865 | 0.393 | | Initial Hb (×109/L) | | | 0.745 | 0.462 |
|
|
